Table 3.
Change scores on IPSS by treatment regimen according to baseline IPSS score
| Baseline IPSS (8–13) | Baseline IPSS (14–19) | Baseline IPSS (≥20) | ||||
|---|---|---|---|---|---|---|
| n | Mean change | n | Mean change | n | Mean change | |
| Watchful waiting, mean (SD) | 64 | 0.5 (3.1) | 46 | 3.0 (2.9)1 | – | |
| Monotherapy, mean (SD) | ||||||
| AB | 87 | 2.4 (2.6) | 171 | 4.6 (3.5)2,3 | 118 | 7.6 (4.7)5,6 |
| 5ARI | – | 34 | 5.2 (4.4)3 | 45 | 9.0 (6.0)5,7 | |
| HESr | 269 | 1.7 (3.3) | 256 | 4.2 (3.7)1,2 | 106 | 7.9 (5.3)6,7 |
| Combination therapy, mean (SD) | ||||||
| AB + 5ARI | – | 25 | 4.4 (4.6)4 | 58 | 9.8 (6.5) | |
| AB + HESr | 32 | 2.8 (2.8) | 84 | 5.0 (3.4)4 | 86 | 9.5 (5.1) |
Groups with <25 patients were excluded from the analysis due to small sample size and a high degree of variability in results
Numbers in superscript indicate the results of statistical testing
If there is no superscript number, then it was not possible to test for significance due to differences in the mean IPSS baseline score
IPSS International Prostate Symptom Score, BII Benign Prostatic Hyperplasia Impact Index, AB α- blockers, 5ARI 5α-reductase inhibitors, HESr hexanic extract of Serenoa repens
1Statistically significant difference observed at p < 0.05 between groups with the same superscript number
2,3,4,5,6,7,8,9,10No statistically significant differences observed between groups with the same superscript number